Hirohiko Shibayama1, Philippe Moreau2, Meletios Dimopoulos3, Shotaro Hagiwara4,5, Hiroshi Handa6, Shuji Ozaki7, Martina A. Sersch8, Mei Huang8, Shinsuke Iida9 (1.Hematol. & Oncol., Osaka Univ. Grad. Sch., Osaka, Japan, 2.Hematol., Univ. Hosp. Hotel-Dieu, Nantes, France, 3.Clin. Ther., Univ. Athens, Athens, Greece, 4.Hematol., Ctr. Hosp. Natl. Ctr. Global Health Med., Tokyo, Japan, 5.Hematol., Tokyo Women's Med. Univ., Tokyo, Japan, 6.Hematol., Gunma Univ. Grad. Sch., Maebashi, Japan, 7.Hematol., Tokushima Pref. Ctr. Hosp., Tokushima, Japan, 8.Amgen Inc., Thousand Oaks, USA, 9.Hematol. & Oncol., Nagoya City Univ. Grad. Sch., Nagoya, Japan)
Session information
Oral Session
Oral Session 1-10C MM: Proteasome inhibitors
Fri. Oct 12, 2018 3:10 PM - 4:10 PM No.10 (Osaka International Convention Center, 10F 1009)
Chair: Michihide Tokuhira (Saitama Medical Center, Saitama Medical University, Japan)
Yu Abe, Kanji Miyazaki, Kota Sato, Yumiko Yoshiki, Kiyoshi Okazuka, Nobuhiro Tsukada, Tadao Ishida, Kenshi Suzuki (Department of hematology, Japanese Red Cross Medical Center, Tokyo, Japan)
Chihiro Kuwabara, Yuhei Nagao, Katsuhiro Shono, Masahiro Onoda, Akira Yokota (Department of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan)
Yoshiaki Abe, Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue (Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center)
Noriko Nishimura1, Anna Nishihara1, Norihito Inoue1, Yoshiharu Kusano1, Yuko Mishima1, Masahiro Yokoyama1, Kiyohiko Hatake2, Yasuhito Terui1 (1.Hematol./Oncol., The Cancer Institute Hospital of JFCR, 2.Hematol., International University of Health and Welfare, Tokyo, Japan)
Michihide Tokuhira, Yuka Tanaka, Yasuyuki Takahashi, Yuta Kimura, Tatsuki Tomikawa, Junichi Watanabe, Tomoe Anan, Morihiko Sagawa, Takayuki Tabayashi, Reiko Watanabe, Masahiro Kizaki (Department of Hematology, Saitama Medical Center, Saitama Medical University, Japan)